mizolastine

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1992-2018
051019922018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
BACKGROUND An IgE-mediated allergic reaction to an antihistamine sounds like a paradox and is rare. OBJECTIVE To describe 2… (More)
Is this relevant?
2003
2003
BACKGROUND Treatment of primary acquired cold urticaria (CU) is quite difficult because of variable clinical effectiveness and… (More)
Is this relevant?
2002
2002
BACKGROUND Levocetirizine is the active enantiomer of cetirizine, a potent drug with little metabolism widely used for allergic… (More)
Is this relevant?
2001
2001
Mizolastine is a second generation antihistamine agent approved in Europe for the treatment of allergic rhinitis and skin… (More)
  • figure 1
  • figure 2
  • table I
  • table II
  • table III
Is this relevant?
2000
2000
AIM To assess the long-term safety and efficacy of the H1-receptor antagonist mizolastine in the symptomatic treatment of chronic… (More)
Is this relevant?
1998
1998
A population analysis of the kinetics of mizolastine was performed from concentrations on 449 allergic patients, using the… (More)
  • figure 1
  • table I
  • table II
  • figure 2
  • figure 3
Is this relevant?
1996
1996
A two-centre, double-blind, randomized, placebo (P)-controlled, parallel-group study was conducted in the UK to examine the… (More)
Is this relevant?
1996
1996
Mizolastine is a new, nonsedating antihistamine providing satisfactory symptom relief in allergic rhinitis and urticaria. The… (More)
Is this relevant?
1995
1995
1. Mizolastine, a new benzimidazole derivative with potent selective, non-sedative H1-histamine antagonist activity was compared… (More)
Is this relevant?
1994
1994
The acute effect of doses of mizolastine 5, 10, 20 and 40 mg, an active control (clemastine 2 mg) and placebo on actual car… (More)
  • figure 1
  • figure 3
  • figure 5
Is this relevant?